










www.MedChemExpress.com

Inhibitors, Agonists, Screening Libraries

Molecular Glue

Protein degradation agents based on the ubiquitin-proteasome pathway include a part of molecular glues. Molecular glues are a class of small molecule compounds that can induce or stabilize the interaction between proteins. If one of the protein is ubiquitin ligase, molecular glue can cause another protein to undergo ubiquitin modification and degradation through the proteasome pathway, which is similar to PROTAC. However, these molecules are classified as ligand for E3 ligase as functional molecules in subsequent classification. Older drugs, thalidomide, lenalidomide, and pomalidomide, together with CC-90009 and CC-92480 reported later all belong to this category.

Molecular Glue

<p>(S)-Thalidomide (S)-(-)-Thalidomide)</p> <p>Cat. No.: HY-14658A</p> <p>(S)-Thalidomide ((S)-(-)-Thalidomide) is the S-enantiomer of Thalidomide. (S)-Thalidomide has immunomodulatory, anti-inflammatory, antiangiogenic and pro-apoptotic effects. (S)-Thalidomide induces teratogenic effects by binding to cereblon (CRBN).</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>Eragidomide (CC-90009)</p> <p>Cat. No.: HY-130800</p> <p>Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4^{CRBN} to selectively target GSPT1 for ubiquitination and proteasomal degradation.</p> <p>Purity: 99.51% Clinical Data: Phase 2 Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 
<p>Lenalidomide (CC-5013)</p> <p>Cat. No.: HY-A0003</p> <p>Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator.</p> <p>Purity: 99.91% Clinical Data: Launched Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g</p> 	<p>Lenalidomide hemihydrate (CC-5013 hemihydrate)</p> <p>Cat. No.: HY-A0003B</p> <p>Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator.</p> <p>Purity: 99.95% Clinical Data: Launched Size: 10 mM × 1 mL, 100 mg, 500 mg</p> 
<p>Lenalidomide hydrochloride (CC-5013 hydrochloride)</p> <p>Cat. No.: HY-A0003A</p> <p>Lenalidomide hydrochloride (CC-5013 hydrochloride), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hydrochloride is an orally active immunomodulator.</p> <p>Purity: >98% Clinical Data: Launched Size: 1 mg, 5 mg</p> 	<p>Mezigdomide (CC-92480)</p> <p>Cat. No.: HY-129395</p> <p>Mezigdomide (CC-92480), a cereblon E3 ubiquitin ligase modulating drug (CELMoD), acts as a molecular glue. Mezigdomide shows high affinity to cereblon, resulting in potent antimyeloma activity.</p> <p>Purity: 98.02% Clinical Data: Phase 2 Size: 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Pomalidomide (CC-4047)</p> <p>Cat. No.: HY-10984</p> <p>Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.</p> <p>Purity: 99.96% Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg</p> 	<p>Thalidomide D4</p> <p>Cat. No.: HY-14658S</p> <p>Thalidomide D4 is a deuterium labeled Thalidomide. Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a K_d of ~250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p> 